FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890331370> ?p ?o ?g. }

• W2890331370 endingPage "276" @default.
• W2890331370 startingPage "269" @default.
• W2890331370 abstract "Hemophagocytic lymphohistiocytosis is an overwhelming systemic inflammatory process that is life-threatening if not treated appropriately. We analyzed prognostic factors in patients with secondary hemophagocytic lymphohistiocytosis excluding malignancy. In this retrospective study, we analyzed 126 adult cases between 2001 and 2017. Treatment was based on dexamethasone with or without etoposide and cyclosporine. Patients who achieved a complete response by 4 weeks were defined as early stable responders, those who failed to achieve a complete response but showed continuous improvement until 8 weeks were defined as late responders, and those whose conditions waxed and waned until 8 weeks were defined as unstable responders. Patients with hemophagocytic lymphohistiocytosis caused by Epstein-Barr virus had a worse 5-year overall survival compared to those whose disease was secondary to autoimmune disease, other infections, or unknown causes (25.1% versus 82.4%, 78.7% and 55.5%, respectively; P<0.001). We observed that the overall response rate at 4 weeks was similar, but decreased at 8 weeks in the Epstein-Barr virus subgroup from 75.5% to 51.0%, and finally decreased to 30.6%. Multivariate analysis revealed that 8-week treatment response was the most relevant factor for overall survival. Excluding 8-week response, the presence of Epstein-Barr virus, old age, hyperferritinemia, and thrombocytopenia were associated with poor survival. We established a prognostic model with the parameters: low-risk (score 0-1), intermediate-risk (score 2), and high-risk (score ≥3). These groups had 5-year overall survival rates of 92.1%, 36.8%, and 18.0%, respectively (P<0.001). We found that 8-week treatment response was a good predictor for overall survival, and that Epstein-Barr virus, old age, thrombocytopenia, and hyperferritinemia were associated with poor survival outcomes. Physicians should take care to identify high-risk patients for appropriate treatment strategies." @default.
• W2890331370 created "2018-09-27" @default.
• W2890331370 creator A5021692797 @default.
• W2890331370 creator A5034751203 @default.
• W2890331370 creator A5036020306 @default.
• W2890331370 creator A5044372572 @default.
• W2890331370 creator A5050627824 @default.
• W2890331370 creator A5055206475 @default.
• W2890331370 creator A5059291757 @default.
• W2890331370 creator A5079417302 @default.
• W2890331370 creator A5081217020 @default.
• W2890331370 creator A5084426605 @default.
• W2890331370 creator A5085429434 @default.
• W2890331370 creator A5086415059 @default.
• W2890331370 date "2018-09-13" @default.
• W2890331370 modified "2023-10-14" @default.
• W2890331370 title "Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy" @default.
• W2890331370 cites W143239180 @default.
• W2890331370 cites W1574141134 @default.
• W2890331370 cites W1988993642 @default.
• W2890331370 cites W1993810850 @default.
• W2890331370 cites W2001492097 @default.
• W2890331370 cites W2008299431 @default.
• W2890331370 cites W2012471701 @default.
• W2890331370 cites W2013522127 @default.
• W2890331370 cites W2014278172 @default.
• W2890331370 cites W2028846478 @default.
• W2890331370 cites W2029693047 @default.
• W2890331370 cites W2029782045 @default.
• W2890331370 cites W2030108552 @default.
• W2890331370 cites W2032052215 @default.
• W2890331370 cites W2034486605 @default.
• W2890331370 cites W2039091069 @default.
• W2890331370 cites W2055476027 @default.
• W2890331370 cites W2057280285 @default.
• W2890331370 cites W2064037171 @default.
• W2890331370 cites W2078922411 @default.
• W2890331370 cites W2083452683 @default.
• W2890331370 cites W2087246109 @default.
• W2890331370 cites W2088301075 @default.
• W2890331370 cites W2088399131 @default.
• W2890331370 cites W2109479983 @default.
• W2890331370 cites W2122161660 @default.
• W2890331370 cites W2133944586 @default.
• W2890331370 cites W2138799962 @default.
• W2890331370 cites W2141361337 @default.
• W2890331370 cites W2144510654 @default.
• W2890331370 cites W2146680365 @default.
• W2890331370 cites W2155477306 @default.
• W2890331370 cites W2162251899 @default.
• W2890331370 cites W2162676322 @default.
• W2890331370 cites W2162777258 @default.
• W2890331370 cites W2164925047 @default.
• W2890331370 cites W2173174278 @default.
• W2890331370 cites W2282446718 @default.
• W2890331370 cites W23552851 @default.
• W2890331370 cites W2372386187 @default.
• W2890331370 doi "https://doi.org/10.3324/haematol.2018.198655" @default.
• W2890331370 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6355492" @default.
• W2890331370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30213834" @default.
• W2890331370 hasPublicationYear "2018" @default.
• W2890331370 type Work @default.
• W2890331370 sameAs 2890331370 @default.
• W2890331370 citedByCount "50" @default.
• W2890331370 countsByYear W28903313702019 @default.
• W2890331370 countsByYear W28903313702020 @default.
• W2890331370 countsByYear W28903313702021 @default.
• W2890331370 countsByYear W28903313702022 @default.
• W2890331370 countsByYear W28903313702023 @default.
• W2890331370 crossrefType "journal-article" @default.
• W2890331370 hasAuthorship W2890331370A5021692797 @default.
• W2890331370 hasAuthorship W2890331370A5034751203 @default.
• W2890331370 hasAuthorship W2890331370A5036020306 @default.
• W2890331370 hasAuthorship W2890331370A5044372572 @default.
• W2890331370 hasAuthorship W2890331370A5050627824 @default.
• W2890331370 hasAuthorship W2890331370A5055206475 @default.
• W2890331370 hasAuthorship W2890331370A5059291757 @default.
• W2890331370 hasAuthorship W2890331370A5079417302 @default.
• W2890331370 hasAuthorship W2890331370A5081217020 @default.
• W2890331370 hasAuthorship W2890331370A5084426605 @default.
• W2890331370 hasAuthorship W2890331370A5085429434 @default.
• W2890331370 hasAuthorship W2890331370A5086415059 @default.
• W2890331370 hasBestOaLocation W28903313701 @default.
• W2890331370 hasConcept C126322002 @default.
• W2890331370 hasConcept C167135981 @default.
• W2890331370 hasConcept C203014093 @default.
• W2890331370 hasConcept C2522874641 @default.
• W2890331370 hasConcept C2776694085 @default.
• W2890331370 hasConcept C2778119113 @default.
• W2890331370 hasConcept C2779079688 @default.
• W2890331370 hasConcept C2779134260 @default.
• W2890331370 hasConcept C2779399171 @default.
• W2890331370 hasConcept C2780401358 @default.
• W2890331370 hasConcept C2781375147 @default.
• W2890331370 hasConcept C38180746 @default.
• W2890331370 hasConcept C71924100 @default.
• W2890331370 hasConcept C90924648 @default.
• W2890331370 hasConceptScore W2890331370C126322002 @default.

• next